SCHEMBL4377310

SCHEMBL4377310

CCCN1CCN(C=CC(=O)c2ccc(Br)cc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.60
NPC1 O15118 4/20 0.60
KMT2A Q03164 5/20 0.46
MEN1 O00255 3/20 0.46
GPR183 P32249 2/20 0.46
ALDH1A1 P00352 7/20 0.44
MAPT P10636 5/20 0.44
USP2 O75604 5/20 0.44
ALOX12 P18054 3/20 0.44
LMNA P02545 3/20 0.43
RECQL P46063 2/20 0.43
HTT P42858 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
MAPK1 P28482 3/20 0.43
POLB P06746 2/20 0.43
HSP90AA1 P07900 1/20 0.43
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CYP1B1 Q16678 1/20 0.42
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4376217 0.88 MAPT (0.45) RAB9ANPC1KMT2AMEN1ALDH1A1
SCHEMBL4383186 0.86 TSHR (0.45) RAB9ANPC1KMT2AMEN1ALDH1A1
SCHEMBL1580934 0.84 RAB9A (0.68) RAB9ANPC1KMT2AMEN1ALDH1A1
SCHEMBL4375406 0.84 ALDH1A1 (0.49) RAB9ANPC1KMT2AMEN1ALDH1A1
SCHEMBL4383715 0.84 HTT (0.43) RAB9ANPC1KMT2AMEN1ALDH1A1
SCHEMBL4377341 0.82 ALDH1A1 (0.56) KMT2AALDH1A1LMNAHPGDSMN1; SMN2
SCHEMBL4382095 0.81 KDM2B (0.50) RAB9ANPC1KMT2AMEN1ALDH1A1
SCHEMBL4377283 0.81 HRH3 (0.50) RAB9ANPC1KMT2AMEN1ALDH1A1
SCHEMBL4380698 0.78 DRD2 (0.51) NPC1KMT2AMEN1ALDH1A1MAPT
SCHEMBL4378980 0.78 AR (0.47) KMT2AMEN1ALDH1A1MAPTRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP claimed
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113968-A1 Substituted piperazines and diazepanes HRH3, HRH4, HRH1 RAB9A 3209/4885NPC1 1743/4885KMT2A 295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.